Request an invite

Kymriah: how long were the pivotal tox studies?

tisagenlecleucel · CD19 CAR-T
Longest pivotal study
31 weeks
“An in vivo study was conducted to evaluate toxicity and BD in tumor-bearing mice receiving i.v. injection of CTL019 at 1, 5, and 20x106 cells/mouse and observed up to Day 217 post-injection (p.i.) with three terminal sacrifices.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Pivotal GLP studies
No GLP tox; non-GLP biotoxicity/BD study in B-ALL tumor-bearing immunodeficient mice, single IV, to Day 217
“The nonclinical toxicology studies were not conducted in compliance with Good Laboratory Practice (GLP), because there was no independent Quality Assurance (QA) audit of integral study parts and raw data storage was not applied in compliance with GLP regulations.”
✓ VerifiedEMA assessment report, p. 28Source ↗
Route in tox
Intravenous
“Route of Administration Intravenous route of administration”
✓ VerifiedFDA pharmacology/toxicology review, p. 15Source ↗

Same question, other cell therapies

Abecma

idecabtagene vicleucel · BCMA CAR-T
12 weeks

Alofisel

darvadstrocel · Allogeneic adipose MSC
26 weeks

Amtagvi

lifileucel · TIL therapy
0 (no in vivo tox study)

Aucatzyl

obecabtagene autoleucel · CD19 CAR-T
2 weeks

Breyanzi

lisocabtagene maraleucel · CD19 CAR-T
14 weeks

Carvykti

ciltacabtagene autoleucel · BCMA CAR-T
14 weeks

ChondroCelect

characterised viable autologous cartilage cells · Autologous chondrocytes
53 weeks

Ebvallo

tabelecleucel · EBV-specific allogeneic T cells
20 weeks

Encelto

revakinagene taroretcel · CNTF (encapsulated RPE cell implant)
26 weeks

Gintuit

allogeneic cultured keratinocytes and fibroblasts in bovine collagen · Allogeneic keratinocytes + fibroblasts
52 weeks

Holoclar

autologous corneal epithelial cells containing limbal stem cells · Autologous limbal stem cells
0 (no in vivo tox study)

Lantidra

donislecel · Allogeneic pancreatic islets
0 (no in vivo tox study)

MACI

autologous cultured chondrocytes on porcine collagen membrane · Autologous chondrocytes
53 weeks

Omisirge

omidubicel · Expanded cord blood HPC
12 weeks

Provenge

sipuleucel-T · PAP-GM-CSF (autologous APC)
6 weeks

Rethymic

allogeneic processed thymus tissue · Allogeneic thymus tissue
39 weeks

Ryoncil

remestemcel-L · Allogeneic BM-MSC
26 weeks

Spherox

spheroids of autologous matrix-associated chondrocytes · Autologous chondrocyte spheroids
39 weeks

StrataGraft

allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen · Allogeneic keratinocytes + fibroblasts
20 weeks

Tecartus

brexucabtagene autoleucel · CD19 CAR-T
30 weeks

Tecelra

afamitresgene autoleucel · MAGE-A4 TCR-T
0 (no in vivo tox study)

Yescarta

axicabtagene ciloleucel · CD19 CAR-T
30 weeks

Zalmoxis

allogeneic T cells modified with HSV-TK / dLNGFR (nalotimagene carmaleucel) · HSV-TK suicide-gene T cells
3 weeks

Zemcelpro

dorocubicel · UM171-expanded cord blood CD34+
28 weeks

Laviv

azficel-T · Autologous fibroblasts
Not stated in public reviews

Tregzi

allogeneic Treg immunotherapy with HSPC and T cells (Orca-T) · Allogeneic Treg + HSPC + Tcon
Not stated in public reviews

Summary across all 27 cell therapies →